The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | LLM lymphoma highlights: ATLL
Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, comments on data on adult T-cell leukemia/lymphoma (ATLL) from the LLM meeting. Although studies evaluating induction regimens did not show improvements for patients with ATLL, novel promising targets are currently being explored. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
